相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Emmanuel Bachy et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S. Horwitz et al.
ANNALS OF ONCOLOGY (2022)
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
Gerald G. Wulf et al.
LEUKEMIA (2021)
Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study
Annalisa Chiappella et al.
BLOOD (2021)
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
Jonathan E. Brammer et al.
BLOOD (2021)
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
Francois Lemonnier et al.
BLOOD ADVANCES (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Patrick B. Johnston et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Lorenzo Falchi et al.
BLOOD (2021)
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
Jia Ruan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas
Donald C. Moore et al.
ANNALS OF PHARMACOTHERAPY (2020)
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
Reiji Fukano et al.
CANCER SCIENCE (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Recent Update of HDAC Inhibitors in Lymphoma
I-Chung Chen et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A plus CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression
Deepa Jagadeesh et al.
BLOOD (2020)
Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
Jia Ruan et al.
BLOOD (2020)
Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma
Emmanuel Bachy et al.
BLOOD (2020)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL LYMPHOMA: PHASE II RESULTS
M. Lunning et al.
HEMATOLOGICAL ONCOLOGY (2019)
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas
Alex F. Herrera et al.
BLOOD (2019)
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Zeina Al-Mansour et al.
LEUKEMIA & LYMPHOMA (2019)
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Michelle A. Fanale et al.
BLOOD (2018)
Novel insights into the pathogenesis of T-cell lymphomas
John S. Van Arnam et al.
BLOOD (2018)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma
Francois Lemonnier et al.
BLOOD (2018)
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Steven M. Horwitz et al.
BLOOD (2018)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study
Martin Bjerregard Pedersen et al.
BLOOD (2017)
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial
Ranjana H. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
CD30 Expression by B and T Cells A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified
Arantza Onaindia et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Pier Luigi Zinzani et al.
HAEMATOLOGICA (2016)
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Pier Luigi Zinzani et al.
HAEMATOLOGICA (2016)
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study
Takashi Ishida et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Francine Foss et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Final Report of a Phase 2 Clinical Trial of Lenalidomide Monotherapy for Patients With T-Cell Lymphoma
Ethan Toumishey et al.
CANCER (2015)
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry
Irene Biasoli et al.
HEMATOLOGICAL ONCOLOGY (2015)
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
Georg Hopfinger et al.
ANNALS OF HEMATOLOGY (2014)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Edgardo R. Parrilla Castellar et al.
BLOOD (2014)
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
Tianjiao Wang et al.
BLOOD (2014)
Cellular origin of T-cell lymphomas
Laurence de Leval et al.
BLOOD (2014)
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz et al.
BLOOD (2014)
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
Javeed Iqbal et al.
BLOOD (2014)
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Bertrand Coiffier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma
Mamiko Sakata-Yanagimoto et al.
NATURE GENETICS (2014)
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
Teresa Palomero et al.
NATURE GENETICS (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial
C. Binder et al.
ANNALS OF HEMATOLOGY (2013)
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
CD30 expression in peripheral T-cell lymphomas
Elena Sabattini et al.
HAEMATOLOGICA (2013)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Concise Drug Review: Azacitidine and Decitabine
Ellen J. B. Derissen et al.
ONCOLOGIST (2013)
Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Etude des Lymphomes de l'Adulte Trials
David Sibon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
Francesco d'Amore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Christos Vaklavas et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2012)
Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
H. C. Kluin-Nelemans et al.
ANNALS OF ONCOLOGY (2011)
New drug therapies in peripheral T-cell lymphoma
Rebecca A. Howman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
Kazuhito Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy
Liuyan Jiang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
Peter Reimer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Andrea Gallamini et al.
BLOOD (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Madeleine Duvic et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score
Philip Went et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
A Gallamini et al.
BLOOD (2004)
CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified
T Ishida et al.
CLINICAL CANCER RESEARCH (2004)
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
KJ Savage et al.
ANNALS OF ONCOLOGY (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
